Cancer Genetics (NASDAQ:CGIX) has been assigned a $6.00 price target by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price target would suggest a potential upside of 215.79% from the stock’s current price.
A number of other brokerages have also weighed in on CGIX. Maxim Group set a $6.00 price objective on shares of Cancer Genetics and gave the stock a “buy” rating in a report on Wednesday, December 13th. ValuEngine upgraded shares of Cancer Genetics from a “strong sell” rating to a “sell” rating in a report on Friday. Finally, Zacks Investment Research upgraded shares of Cancer Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $5.56.
Shares of Cancer Genetics (NASDAQ CGIX) remained flat at $$1.90 during midday trading on Tuesday. The company had a trading volume of 61,904 shares, compared to its average volume of 166,242. Cancer Genetics has a 1 year low of $1.70 and a 1 year high of $5.30. The company has a market capitalization of $51.95, a PE ratio of -2.29 and a beta of 1.14. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.18.
In related news, Director John Pappajohn bought 150,000 shares of the firm’s stock in a transaction on Friday, December 8th. The stock was acquired at an average cost of $1.86 per share, for a total transaction of $279,000.00. Following the purchase, the director now owns 2,781,204 shares in the company, valued at $5,173,039.44. The acquisition was disclosed in a filing with the SEC, which is available through this link. 21.30% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Northern Trust Corp raised its stake in Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares during the last quarter. Granahan Investment Management Inc. MA raised its stake in Cancer Genetics by 26.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after buying an additional 49,371 shares during the last quarter. Perkins Capital Management Inc. raised its stake in Cancer Genetics by 22.7% during the 4th quarter. Perkins Capital Management Inc. now owns 989,700 shares of the medical research company’s stock valued at $1,831,000 after buying an additional 183,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Cancer Genetics by 61.9% during the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after acquiring an additional 197,619 shares during the period. Institutional investors and hedge funds own 11.74% of the company’s stock.
Cancer Genetics Company Profile
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.